LAMINAR PHARMA

INVESTMENT OPPORTUNITY SHEET

COMPANY: Laminar Pharmaceuticals

WEB: https://laminarpharma.com

SECTOR: Biotechnology

Funding round:
20M €
Pre-money valuation:
260M €

PROJECT

LAM561 is in phase 3 for the treatment of glioblastoma patients and is expected to apply for marketing authorization in 2026. This product has potential against other types of cancer, which reduces the risk of investment. Other Laminar products that have been licensed to other independent companies are also showing great potential in developed clinical studies, which validates our technology platform (MELITHERAPY) and increases the value of the company. In 2023 Laminar received the prestigious award for Technology Innovation by CEPYME (SMEs confederation of companies in Spain).

Clinical studies conducted so far demonstrate the high safety and therapeutic activity of LAM561. The current round of financing will allow us to brought it to the market.

TEAM

Pablo V. Escribá, PhD
CEO and Founder

Victoria Lladó, Ph.D.
General Manager, U.S.A.

Paula Fernandez, PhD
CSO

Antonio González
COO

David Roberto
CFO

Adrian McNicholl, PhD
Chief Clinical Operations

Cati Ana Rosselló
Director of CMC

JJ Muruzabal, PhD
Product Development

Richard Taylor
Regulatory & Medical

Emilce Cano
Director, Intellectual Property

Joe Dillon
CBO

PROBLEM

Cancer is the second cause of death in the world, Laminar Pharma has a technological platform that contributes 9% of the drugs under development by Spanish companies. The first product, LAM561, is currently being developed against brain cancer (glioblastoma, GBM). Only 4% of GBM patients survive after 5 years. Following the application for this indication in 2026, Laminar will seek approval to market LAM561 to treat other types of cancer.

SOLUTION

Laminar has developed an **oral** drug **with no serious adverse events** and great potential to treat a wide variety of tumors.

The current study, MIN-003-1806, is a clinical phase 2B/3. Therefore, it is the last clinical study that will allow the commercialization of this product if resuls are positive. Furthermore, this product would be administered as "standard of care" in first-line treatment in patients with GBM.

First independent experts report (Oct23) about safety & ethics & futility came out positive. **Second independent report (Feb24) analysing efficacy was also positive** "continue without any modification"). **Third independent PFS report (Nov24) analysing efficacy was also positive** "continue without any modification")

CURRENT FUNDING ROUND

The objective of the current round is to obtain financing of up to 20M euros to complement financing through other financial instruments (tax lease, debt, Upfront,...), and complete the last clinical study and dossier-related activities that will allow us to start selling LAM561.

NEXT STEPS

With the 140 patients recruited last June 2024 , we are in the late stage of the clinical trial. In 2026 we will have the final OS open read-out of the data. Then we will fill for marketing authorisation. Laminar is in negotiations with Pharma companies to out-license LAM561 globally. We plan to develop the rest of our pipeline with the benefits derived from LAM561.

USE OF THE INVESTMENT

0.5% Basic R&D
1% Pre-clinical R&D
4.5% Pediatric Clinical Study in USA
94% Clinical Study Phase 3 Europe

MARKET

The market for LAM561 could be 1,000-5,000 million euros, due to its extraordinary low toxicity and potential efficacy against brain tumors and other types of solid tumors.

FINANCIAL FORECAST

000' Euros	2024	2025	2026	2027	2028
Turnover	10.743	11.938	42.396	76.858	139.879
EBIT	-55	3.136	24.713	36.367	89.025
Cash	11.456	10.320	24.741	49.311	121.067
Equity	38.648	49.976	71.540	103.581	180.762

EXIT & STRATEGY

In 2022, Laminar obtained **Fast Track designation**, which joins the designation in October 2021 as an **Orphan Drug in the US**. This regulatory scenario and the alliance that is being negotiated with a pharmaceutical company will allow a revaluation of Laminar in the short term. Subsequently, the publication of the results of our clinical studies and the approval to market LAM561 will allow further increases in valuation. The revaluation potential in 2-3 years could be similar to that of other companies that introduce new medicines on the market whose average value is greater than **€1,000 million**.

Annual dividends and mechanisms to allow the sale of shares are planned to be developed and allow a successful exit to those investors wanting it.